Second, although our study was aimed exclusively at HER2‐negative, HR+ breast cancer to maintain cohort homogeneity, this by definition restricts its translational relevance to other subtypes, that is, triple‐negative or HER2‐positive breast cancer. The gene discussed is ERBB2; the disease is breast cancer.